Drugmaker Gilead Sciences is not only providing the shot in the US, but is also working with governments and health groups in the UK and low-income countries to make these products more available.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

S&P 500, Banco Santander, Gilead Sciences Inc. Read 's Market Analysis on Investing.com ...